Register Login
Register to leave comments
  • News bot Oct. 13, 2025, 9:40 a.m.

    📋 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) - Financial Results

    Filing Date: 2025-05-15

    Accepted: 2025-05-15 16:10:24

    Event Type: Financial Results

    Event Details:

    Reviva Pharmaceuticals Holdings Inc. (RVPH) Reports Q2 2025 Financial Results Reviva Pharmaceuticals Holdings Inc. (RVPH) announced its financial results for the period ending Q2 2025. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 5289404
      • label extension (OLE) trial with 156 completing one
      • year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and biomarker data expected in Q2 2025 – – Registrational Phase 3 RECOVER
      • 2 trial initiation for brilaroxazine expected mid
        • expected in mid-2025
        • expected in Q2 2025
        • targeting a potential New Drug Application (NDA) submission for brilaroxazine in the fourth quarter of 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Assets Prepaid Expenses Other Current Assets 756.07K 666.43K $89.63K +13.45%
    Liabilities Accounts Payable 4.72M 6.28M $-1.56M -24.87%
    Operating Expenses Loss From Operations 6.54M 7.92M $-1.38M -17.47%
    Other Income Expense Interest Expense 11.62K 3.49K $8.13K +233.24%
    Other Income Expense Interest Income 86.11K 173.10K $-86.99K -50.25%
    Other Income Expense Net Loss 6.43M 7.43M $-1.00M -13.46%
    Prepaid Expenses and Other Current Assets 756.07K 666.43K $89.63K +13.45%
    Accounts Payable 4.72M 6.28M $-1.56M -24.87%
    Accrued Liabilities 482.86K 500.62K $-17.75K -3.55%
    Loss from Operations 6.54M 7.92M $-1.38M -17.47%
    Interest Expense 11.62K 3.49K $8.13K +233.24%
    Interest Income 86.11K 173.10K $-86.99K -50.25%
    Net Loss 6.43M 7.43M $-1.00M -13.46%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Reviva Pharmaceuticals Holdings Inc.
    • CIK: 0001742927
    • Ticker Symbol: RVPH
    • Period End Date: 2025-05-15
    • Document Type: 8-K

Search

News categories